Applications including "Swift"

LT206 - Anaysis of Antioxidant capacity by pre-column HPLC using DPPH radical -

LC Technical Note InertSustainSwift C8
LT205 - Anaysis of stable radical DPPH -

LC Technical Note InertSustainSwift C8
LT200 - InertSustain & Inertsil HPLC Columns for Reversed Phase Separation -

LC Technical Note InertSustain C18 InertSustain AQ-C18 InertSustainSwift C18 InertSustain AX-C18 Inertsil ODS-HL Inertsil ODS-4 Inertsil ODS-3 Inertsil ODS-P Inertsil ODS-EP InertSustain C8 Inertsil C8-4 Inertsil C4 Inertsil WP300 C18 Inertsil WP300 C8 Inertsil WP300 C4 InertSustain PFP InertSustain Phenyl InertSustain Phenylhexyl
LB899 - Analysis of Fesoterodine Fumarate -

LC InertSearch InertSustainSwift C18
LB895 - Analysis of Venlafaxine hydrochloride -

LC InertSearch InertSustainSwift C8
LB827 - Analysis of Clobetasone butyrate standard -

LC InertSearch InertSustainSwift C18
LB817 - Analysis of Phospholipids -

LC InertSearch InertSustainSwift C18
LB816 - Analysis of Zoledronic acid -

LC InertSearch InertSustainSwift C18
LB815 - Analysis of Riboflavin (Vitamin B2) and its metabolites -

LC InertSearch InertSustainSwift C18
LB755 - Analysis of Oxaliplatin (Under the Condition of the draft for the Japanese Pharmacopoeia18th supplement II) -

LC InertSearch InertSustainSwift C18
LB715 - Analysis of Toluene and Toluene d8 -

LC InertSearch InertSustainSwift C18
LB704 - Analysis of Phosphate ester flame retardants (PFRs) -

LC InertSearch InertSustainSwift C18
LB703 - Analysis of Phosphate ester flame retardants (PFRs) -

LC InertSearch InertSustainSwift C18
LL038 - Analysis of cannabinoids -

LC InertSearch InertSustainSwift C18
LB695 - Analysis of acetic acid （USP） -

LC InertSearch InertSustainSwift C18
LB682 - Analysis of Acetic acid and Acetic anhydride -

LC InertSearch InertSustainSwift C18
LB672 - Analysis of Stearyl Glycyrrhetinate -

LC InertSearch InertSustainSwift C8
LB669 - Analysis of Rosuvastatin calcium (Under the condition of the Japanese Pharmacopoeia (JP) ) -

LC InertSearch InertSustainSwift C18
LB639 - Analysis of Levetiracetam (Under the Condition of USP42-NF37 1S, Levetiracetam Oral Solution) -

LC InertSearch InertSustainSwift C18
LB636 - Analysis of Levetiracetam (Under the Condition of USP42-NF37 1S, Levetiracetam Tablets) -

LC InertSearch InertSustainSwift C18
LB634 - Analysis of Rivaroxaban (Under the Condition of draft for USP, Rivaroxaban Tablets) -

LC InertSearch InertSustainSwift C18
LB633 - Analysis of Rivaroxaban (Under the Condition of draft for USP) -

LC InertSearch InertSustainSwift C18
LB625 - Analysis of Prasugrel hydrochloride (Under the Condition of USP42-NF37) -

LC InertSearch InertSustainSwift C18
LT166 - Simultaneous Analysis of 12 Soybean Isoflavones -

LC Technical Note InertSustainSwift C18
LT152 - Metal-free Columns for HPLC Part 1 -

LC Technical Note InertSustainSwift C18 InertSustain C18 PEEK Column
LT124 - Analysis of Furfural in Insulating Oil -

LC Technical Note InertSustainSwift C18 InertSustain AQ-C18
LL019 - Analysis of Food Colorants (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB554 - Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine Orally Disintegrating Tablets) -

LC InertSearch InertSustainSwift C18
LB551 - Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe Tablets) -

LC InertSearch InertSustainSwift C18
LB550 - Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe Tablets) -

LC InertSearch InertSustainSwift C18
LB546 - Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) -

LC InertSearch InertSustainSwift C18
LB545 - Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) -

LC InertSearch InertSustainSwift C18
LB535 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustainSwift C8
LB519 - Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustainSwift C18
LB514 - Analysis of Oligonucleotides -

LC InertSearch InertSustainSwift C18
LB511 - Analysis of Parabens, Estradiol and Progesterone -

LC InertSearch InertSustainSwift C18
LB510 - Analysis of Estradiol and Progesterone (Under the Condition of the draft for the Japanese Standards of Quasi-drug Ingredients, Placental Extract) -

LC InertSearch InertSustainSwift C18
LB504 - Analysis of Fipronil -

LC InertSearch InertSustainSwift C18
LB484 - Analysis of Catecholamine metabolite -

LC InertSearch InertSustainSwift C18
LB483 - Analysis of Minocycline Hydrochloride (Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LC InertSearch InertSustainSwift C8
LB472 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C8
LB470 - Simultaneous analysis of Amino acids derivatized with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) -

LC InertSearch InertSustainSwift C18
LB468 - Analysis of Vitamin K（InertSustainSwift C8） -

LC InertSearch InertSustainSwift C8
LB447 - Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (6) 2-Aminophenol and 4-Aminophenol) -

LC InertSearch InertSustainSwift C18 HP
LB440 - Analysis of Myoglobin Digests (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB438 - Analysis of BSA Digests (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB420 - Analysis of Acetaminophen (Under the Condition of the Japanese Pharmacopoeia) （InertSustainSwift C18） -

LC InertSearch InertSustainSwift C18
LB417 - Analysis of Vitamin K (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB413 - Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18
LB412 - Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18
LB408 - Analysis of Fluconazole (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18
LB405 - Analysis of Phenolic antioxidants -

LC InertSearch InertSustainSwift C18
LB399 - Analysis of 9 Drugs (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB397 - Analysis of Glyphosate, Glufosinate and AMPA derivatized with 9-Fluorenylmethyl Chloroformate (FMOC) -

LC InertSearch InertSustainSwift C18
LB395 - Analysis of Acetaminophen and Caffeine -

LC InertSearch InertSustainSwift C18
LB393 - Analysis of Methacrylic acid (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB389 - Analysis of 12 Drugs (InertSustainSwift C18 HP) -

LC InertSearch InertSustainSwift C18 HP
LB383 - Analysis of Angiotensin II receptor blockers (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB373 - Analysis of Cyclophosphamide (Under the Condition of the Japanese Pharmacopoeia, Cyclophosphamide Tablets) -

LC InertSearch InertSustainSwift C18
LB372 - Analysis of Cyclophosphamide (Under the Condition of the Japanese Pharmacopoeia, Cyclophosphamide Tablets) -

LC InertSearch InertSustainSwift C18
LB371 - Analysis of Amlodipine besilate (Under the Condition of the Japanese Pharmacopoeia, Amlodipine Besilate Orally Disintegrating Tablets) -

LC InertSearch InertSustainSwift C18
LB342 - Analysis of Furfral and 5-Hydroxymethylfurfral (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB318 - Analysis of Maleic acid, Fumaric acid and Acrylic acid (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB271 - Analysis of Tulathromycin -

LC InertSearch InertSustainSwift C18
LB270 - Analysis of β-blocker -

LC InertSearch InertSustainSwift C18
LB269 - Analysis of Tetracyclines (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB247 - Analysis of Terbinafine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Terbinafine hydrochloride Cream) -

LC InertSearch InertSustainSwift C18
LB239 - Analysis of Preservatives and Sweetener (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB236 - Analysis of Preservatives and Sweetener (InertSustainSwift C18) -

LC InertSearch InertSustainSwift C18
LB234 - Analysis of Amino acids -

LC InertSearch InertSustainSwift C18
LB233 - Analysis of Amino acids -

LC InertSearch InertSustainSwift C18
LB232 - Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18 HP
LB231 - Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18 HP
LB230 - Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18 HP

Applications including "Swift"

LT206 - Anaysis of Antioxidant capacity by pre-column HPLC using DPPH radical -

LT205 - Anaysis of stable radical DPPH -

LT200 - InertSustain & Inertsil HPLC Columns for Reversed Phase Separation -

LB899 - Analysis of Fesoterodine Fumarate -

LB895 - Analysis of Venlafaxine hydrochloride -

LB827 - Analysis of Clobetasone butyrate standard -

LB817 - Analysis of Phospholipids -

LB816 - Analysis of Zoledronic acid -

LB815 - Analysis of Riboflavin (Vitamin B2) and its metabolites -

LB755 - Analysis of Oxaliplatin (Under the Condition of the draft for the Japanese Pharmacopoeia18th supplement II) -

LB715 - Analysis of Toluene and Toluene d8 -

LB704 - Analysis of Phosphate ester flame retardants (PFRs) -

LB703 - Analysis of Phosphate ester flame retardants (PFRs) -

LL038 - Analysis of cannabinoids -

LB695 - Analysis of acetic acid （USP） -

LB682 - Analysis of Acetic acid and Acetic anhydride -

LB672 - Analysis of Stearyl Glycyrrhetinate -

LB669 - Analysis of Rosuvastatin calcium (Under the condition of the Japanese Pharmacopoeia (JP) ) -

LB639 - Analysis of Levetiracetam (Under the Condition of USP42-NF37 1S, Levetiracetam Oral Solution) -

LB636 - Analysis of Levetiracetam (Under the Condition of USP42-NF37 1S, Levetiracetam Tablets) -

LB634 - Analysis of Rivaroxaban (Under the Condition of draft for USP, Rivaroxaban Tablets) -

LB633 - Analysis of Rivaroxaban (Under the Condition of draft for USP) -

LB625 - Analysis of Prasugrel hydrochloride (Under the Condition of USP42-NF37) -

LT166 - Simultaneous Analysis of 12 Soybean Isoflavones -

LT152 - Metal-free Columns for HPLC Part 1 -

LT124 - Analysis of Furfural in Insulating Oil -

LL019 - Analysis of Food Colorants (InertSustainSwift C18) -

LB554 - Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine Orally Disintegrating Tablets) -

LB551 - Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe Tablets) -

LB550 - Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe Tablets) -

LB546 - Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) -

LB545 - Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) -

LB535 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) -

LB519 - Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) -

LB514 - Analysis of Oligonucleotides -

LB511 - Analysis of Parabens, Estradiol and Progesterone -

LB510 - Analysis of Estradiol and Progesterone (Under the Condition of the draft for the Japanese Standards of Quasi-drug Ingredients, Placental Extract) -

LB504 - Analysis of Fipronil -

LB484 - Analysis of Catecholamine metabolite -

LB483 - Analysis of Minocycline Hydrochloride (Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LB472 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB470 - Simultaneous analysis of Amino acids derivatized with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) -

LB468 - Analysis of Vitamin K（InertSustainSwift C8） -

LB447 - Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (6) 2-Aminophenol and 4-Aminophenol) -

LB440 - Analysis of Myoglobin Digests (InertSustainSwift C18) -

LB438 - Analysis of BSA Digests (InertSustainSwift C18) -

LB420 - Analysis of Acetaminophen (Under the Condition of the Japanese Pharmacopoeia) （InertSustainSwift C18） -

LB417 - Analysis of Vitamin K (InertSustainSwift C18) -

LB413 - Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB412 - Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB408 - Analysis of Fluconazole (Under the Condition of the Japanese Pharmacopoeia) -

LB405 - Analysis of Phenolic antioxidants -

LB399 - Analysis of 9 Drugs (InertSustainSwift C18) -

LB397 - Analysis of Glyphosate, Glufosinate and AMPA derivatized with 9-Fluorenylmethyl Chloroformate (FMOC) -

LB395 - Analysis of Acetaminophen and Caffeine -

LB393 - Analysis of Methacrylic acid (InertSustainSwift C18) -

LB389 - Analysis of 12 Drugs (InertSustainSwift C18 HP) -

LB383 - Analysis of Angiotensin II receptor blockers (InertSustainSwift C18) -

LB373 - Analysis of Cyclophosphamide (Under the Condition of the Japanese Pharmacopoeia, Cyclophosphamide Tablets) -

LB372 - Analysis of Cyclophosphamide (Under the Condition of the Japanese Pharmacopoeia, Cyclophosphamide Tablets) -

LB371 - Analysis of Amlodipine besilate (Under the Condition of the Japanese Pharmacopoeia, Amlodipine Besilate Orally Disintegrating Tablets) -

LB342 - Analysis of Furfral and 5-Hydroxymethylfurfral (InertSustainSwift C18) -

LB318 - Analysis of Maleic acid, Fumaric acid and Acrylic acid (InertSustainSwift C18) -

LB271 - Analysis of Tulathromycin -

LB270 - Analysis of β-blocker -

LB269 - Analysis of Tetracyclines (InertSustainSwift C18) -

LB247 - Analysis of Terbinafine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Terbinafine hydrochloride Cream) -

LB239 - Analysis of Preservatives and Sweetener (InertSustainSwift C18) -

LB236 - Analysis of Preservatives and Sweetener (InertSustainSwift C18) -

LB234 - Analysis of Amino acids -

LB233 - Analysis of Amino acids -

LB232 - Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) -

LB231 - Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) -

LB230 - Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) -

Application Search